Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial (vol 2, pg 565, 2017)

被引：0
作者：
Meyer, T.
Fox, R.
Yt, Ma
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2017年 / 2卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E6 / E6
页数：1
相关论文
共 1 条
  • [1] Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
    Meyer, Tim
    Fox, Richard
    Ma, Yuk Ting
    Ross, Paul J.
    James, Martin W.
    Sturgess, Richard
    Stubbs, Clive
    Stocken, Deborah D.
    Wall, Lucy
    Watkinson, Anthony
    Hacking, Nigel
    Evans, T. R. Jeffry
    Collins, Peter
    Hubner, Richard A.
    Cunningham, David
    Primrose, John Neil
    Johnson, Philip J.
    Palmer, Daniel H.
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (08): : 565 - 575
1